933 related articles for article (PubMed ID: 19614963)
21. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
[TBL] [Abstract][Full Text] [Related]
22. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
[TBL] [Abstract][Full Text] [Related]
23. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
24. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
[TBL] [Abstract][Full Text] [Related]
25. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.
Havla J; Gerdes LA; Meinl I; Krumbholz M; Faber H; Weber F; Pellkofer HL; Hohlfeld R; Kümpfel T
J Neurol; 2011 Sep; 258(9):1665-9. PubMed ID: 21431380
[TBL] [Abstract][Full Text] [Related]
26. [Update on current care guidelines: multiple sclerosis].
Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.
Oturai AB; Koch-Henriksen N; Petersen T; Jensen PE; Sellebjerg F; Sorensen PS
Eur J Neurol; 2009 Mar; 16(3):420-3. PubMed ID: 19364368
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
[TBL] [Abstract][Full Text] [Related]
29. The toronto observational study of natalizumab in multiple sclerosis.
Krysko KM; O'Connor PW
Can J Neurol Sci; 2011 May; 38(3):422-8. PubMed ID: 21515500
[TBL] [Abstract][Full Text] [Related]
30. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M
Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044
[TBL] [Abstract][Full Text] [Related]
32. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
33. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
Berger JR
Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035
[TBL] [Abstract][Full Text] [Related]
34. Long-term effectiveness of glatiramer acetate in clinical practice conditions.
Arnal-García C; Amigo-Jorrin Mdel C; López-Real AM; Lema-Devesa C; Llopis N; Sanchez-de la Rosa R;
J Clin Neurosci; 2014 Dec; 21(12):2212-8. PubMed ID: 25257663
[TBL] [Abstract][Full Text] [Related]
35. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
[TBL] [Abstract][Full Text] [Related]
37. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
38. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
40. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
